Hikma Pharmaceuticals PLC
LSE:HIK
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 722
2 083
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC
Income from Continuing Operations
Hikma Pharmaceuticals PLC
Income from Continuing Operations Peer Comparison
GSK
AZN
VRNA
INDV
DPH
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Income from Continuing Operations
$290m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Income from Continuing Operations
£4.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Income from Continuing Operations
$6.4B
|
CAGR 3-Years
20%
|
CAGR 5-Years
25%
|
CAGR 10-Years
12%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Income from Continuing Operations
-$153.7m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Income from Continuing Operations
-$141m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Income from Continuing Operations
-£27.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Hikma Pharmaceuticals PLC's Income from Continuing Operations?
Income from Continuing Operations
290m
USD
Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Income from Continuing Operations amounts to 290m USD.
What is Hikma Pharmaceuticals PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-1%
Over the last year, the Income from Continuing Operations growth was 96%. The average annual Income from Continuing Operations growth rates for Hikma Pharmaceuticals PLC have been -15% over the past three years , -4% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet
